Wolverine Trading, LLC Cerevel Therapeutics Holdings, Inc. Call Options Transaction History

Wolverine Trading, LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 14, 2024	SELL	$38.96 - $42.75 $38,960 - $42,750	-1,000 Reduced 5.08%	18,700 $764,000
Q1 2024 May 15, 2024	SELL	$40.88 - $43.27 $1.06 Million - $1.12 Million	-25,900 Reduced 56.8%	19,700 $832,000
Q4 2023 Feb 14, 2024	BUY	$20.27 - $42.44 $441,886 - $925,192	21,800 Added 91.6%	45,600 $1.93 Million
Q3 2023 Nov 15, 2023	BUY	$20.26 - $31.91 $482,188 - $759,458	23,800 New	23,800 $519,000
Q1 2023 May 15, 2023	BUY	$22.82 - $35.32 $766,752 - $1.19 Million	33,600 Added 260.47%	46,500 $1.12 Million
Q4 2022 Feb 14, 2023	BUY	$25.35 - $31.96 $126,750 - $159,800	5,000 Added 63.29%	12,900 $407,000
Q3 2022 Nov 14, 2022	BUY	$25.5 - $41.42 $12,750 - $20,710	500 Added 6.76%	7,900 $220,000
Q2 2022 Aug 15, 2022	BUY	$20.62 - $37.15 $152,588 - $274,910	7,400 New	7,400 $200,000

5.01M

3.3K

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Wolverine Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Wolverine Trading, LLC with notifications on news.